We report a case of Candida glabrata sepsis associated with chorioamnionitis in an in vitro fertilization-assisted pregnancy. There is a strong association between C. glabrata chorioamnionitis and assisted fertility techniques. Candida glabrata chorioamnionitis presents unique management challenges.
Ultrasonography on day 4 showed normal amniotic fluid volume and fetal parameters for both twins. Repeat ultrasonography on days 10 and 13 showed reduced amniotic fluid around twin 2, consistent with premature rupture of membranes. Ultrasonography on day 17 revealed new oligohydramnios of twin 1 and anhydramnios of twin 2, but ongoing filling of fetal bladders. Ultrasonography on day 20 showed some reaccumulation of fluid around twin 2. Growth and blood vessel Doppler ultrasounds of both twins were normal on all scans.
Blood cultures remained negative after the initiation of antifungal therapy. The organism was resistant to fluconazole (minimum inhibitory concentration [MIC] >256 µg/mL) and itraconazole (MIC = 8.0), but sensitive to voriconazole (MIC = 1.0), amphotericin B (MIC = 1.0), 5-flucytosine (MIC = 0.12), and caspofungin (MIC = 0.5). On day 10, oral 5-flucytosine 150 mg/kg daily was added to liposomal amphotericin. The 5-flucytosine dose was reduced after 8 days due to mild neutropenia, then substituted by intravenous caspofungin 50 mg daily on day 20. On day 21, after 17 days of intravenous antifungal treatment, spontaneous labor began and both twins were delivered stillborn. The patient developed rigors and hypotension. However, repeat blood cultures were negative and there was no evidence of endophthalmitis. She was treated successfully with caspofungin for 7 days, then oral voriconazole for 7 days.
The parents declined autopsy. Histopathology of the first placenta showed a small area of infarction but no evidence of inflammation or infection. The tissues of twin 2 showed profuse C. glabrata in the fetal membranes (see Supplementary Data), with fewer yeasts on the umbilical cord and fetal placental surface. There were few inflammatory cells in the areas containing yeasts, and culture of placental tissue was negative.
DISCUSSION
Candida glabrata, formerly known as Torulopsis glabrata, is a nonpseudohyphae-forming Candida species. Candida glabrata lower urogenital tract carriage rates during pregnancy range from 2% to 8%. Experimental data suggest reduced virulence compared to Candida albicans, with an absence of hyphae production and less adhesive capacity [1] . This, however, contrasts with extremely high fetal mortality with invasive C. glabrata infections during pregnancy.
There has been historical underdetection, and hence underreporting, of C. glabrata infection. Reliable identification is possible using chromogenic culture media, newer biochemical and molecular techniques, and Gomori-Grocott or Periodic Acid-Schiff staining on histological specimens. In contrast to C. albicans, C. glabrata infections typically do not demonstrate subchorionic microabscesses or umbilical cord nodules [2] .
Candida albicans chorioamnionitis involves the placentas of 0.5% of pregnancies [3] ; C. glabrata chorioamnionitis is much less commonly reported. Review of the 16 published confirmed cases of C. glabrata chorioamnionitis (Table 1) reveals that 63% are associated with IVF, and 81% with some form of instrumentation. The first IVF-associated case was reported in 1997 [4] . Candida glabrata is less able than C. albicans to invade and migrate across intact chorionic membranes [5] . This provides a mechanistic hypothesis for the strong association with assisted fertility and the rarity of C. glabrata chorioamnionitis without some form of instrumentation. Because C. glabrata has difficulty penetrating intact membranes, it benefits from direct inoculation into the uterus. This can occur through IVF techniques, coexisting intrauterine contraceptive device, cervical stitch, rupture of membranes, and with amniocentesis or chorionic villous sampling. The process of IVF allows potential C. glabrata uterine contamination at several points. Transvaginal embryo harvest enables inoculation by the mother's cervicovaginal Candida. Candida glabrata contamination of IVF tissue for implantation, via infected semen, is also reported [6] . Transvaginal embryo transfer provides another critical opportunity for inoculation. Despite the association between C. glabrata and IVF techniques, little formal experimental work investigating these particular etiological mechanisms in detail has been published.
Historically, invasive C. glabrata infection was thought to be exclusively endogenously acquired. However, studies have shown the capacity for nosocomial acquisition of C. glabrata [7] . Hence, amniocentesis may theoretically provide a route of transfer. Similarly, chorionic villous sampling, particularly transvaginal, risks inoculation of vaginal flora [8] .
Chorioamnionitis due to C. glabrata usually becomes clinically apparent in the second trimester. It has high lethality with only 31% of the published affected pregnancies having any neonatal survival. To our knowledge, our case is only the fourth report of systemic maternal antifungal treatment for C. glabrata chorioamnionitis prior to delivery, and reflects the longest period of intrauterine antifungal treatment to date.
Candida glabrata has increased resistance to azoles, particularly fluconazole, but is typically sensitive to amphotericin B. Amphotericin B penetrates into all fetal tissues with a long persistence period [9] . However, amphotericin has rarely been utilized for invasive candidal disease in pregnancy, having predominantly been used for treatment of pregnant women with cryptococcal disease, coccidioidomycosis, and blastomycosis [10] . It has been used successfully as an intra-amniotic infusion for C. albicans chorioamnionitis [11] , and for intravenous line-associated C. glabrata sepsis in neonates [12] . Liposomal amphotericin appears equivalent in efficacy and safety during pregnancy.
The echinocandin group of antifungals are recommended by the Infectious Diseases Society of America for disseminated C. glabrata infection [13] . Caspofungin and anidulafungin cross the placenta, but pharmaceutical company data have demonstrated embryotoxicity in animals with early pregnancy use. However, caspofungin has been used very successfully in premature neonates in the context of fluconazole-and amphotericin-resistant Candida parapsilosis sepsis [14] .
Adequate C. glabrata carriage and vulvovaginitis eradication rates are reported using intravaginal boric acid, amphotericin, or flucytosine in women with azole-resistant C. glabrata, or in recalcitrant cases of C. glabrata vulvovaginitis [15] . Asemota et al achieved a successful IVF pregnancy after topical boric acid treatment in a woman whose previous IVF-assisted pregnancy ended in C. glabrata sepsis and fetal loss [16] .
Seventeen days of liposomal amphotericin, with concomitant 5-flucytosine for 10 days, did not eradicate the infection in our patient, despite proven susceptibilities. Given the strength of the relationship between IVF techniques and C. glabrata chorioamnionitis, and the extremely high mortality rate historically, the potential role for screening prior to assisted fertility attempts involving embryo harvest or transfer is raised, as it has been by previous authors [4, 17, 18] . However, a comprehensive screening program may not be justified owing to the rarity of invasive disease despite widespread and increasing use of IVF technologies and the relatively high rates of C. glabrata carriage among pregnant women.
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